通心络胶囊治疗不稳定型心绞痛疗效观察

目的探讨通心络胶囊治疗不稳定型心绞痛的效果与安全性。方法120例不稳定型心绞痛患者随机分为两组：对照组60例，给予常规药物治疗（拜阿司匹林每次100mg，1次／d；倍他乐克12．5mg酌情加减剂量，2次／d；硝酸甘油0．5-1mg，发作时舌下含服；辛伐他汀10mg，10：／d，晚间顿服；低分子肝素5000uiHq12h，使用7d）；观察组60例，在常规药物治疗基础上加用通心络胶囊4粒，30：／d，餐后0．5h口服，4周为1疗程。观察两组患者的总疗效、心绞痛疗效、心电图疗效、血脂、凝血四项等指标变化。结果观察组总有效率83．33％，显效率41．67％，其心绞痛缓解总有效率93．33％，显效率51．67％。心电图疗效总有效率86．67％，显效率41．67％；观察组能够显著降低总胆固醇（TC）和低密度脂蛋白（LDL—C）水平，提高高密度脂蛋白（HDL—C），延长凝血酶时间（TT），与对照组相比上述指标均具有显著差异（P〈0．05）。结论通心络胶囊能够显著缓解不稳定型心绞痛患者的心绞痛症状，改善血脂水平、凝血功能和心肌缺血的心电图表现。

Therapeutic effect of Tongxinluo capsule on unstable angina pectoris

Objective To investigate the clinical therapeutic effect of Tongxinluo capsule on unstable angina pecto- ris. Methods Totally 120 patients with unstable angina pectoris were randomly divided into two groups：control group were treated with regular therapy,including Aspirin 100mg qd, Betaloc 12. 5rag bid, Nitroglycerin 0. 5 - 1.0mg prn, and Simvastatin 10mg qn,low molecular weight heparin iH ql2h for 7 days. In addition to the regular medicines, Tongxinluo group were treated with Tongxinluo （4 capsules tid）, half an hour postprandial oral administration. After treatment for 4 weeks,the total clinical effect,symptom of angina pectoris and other indicators,such as electrocardiogram （ECG） ,blood lipid and coagulant - anticoagulant function were observed and analyzed to evaluate the effect of Tongxinluo. Results In Tongxinluo group, the total clinical effective rate were 83.33% and markedly effective rate was 41.67%. The rates of total and marked alleviation of angina pectoris were 93.33% and 51.67%, respectively. The total and marked improvement rates of ECG were 86. 67% and 41.67%. All the indicators were favorably changed in Tongxinluo group when compared with that of the control group （P 〈 0. 05 ）. Besides ,Tongxinluo capsule significantly reduced the total cholesterol and low density lipoprotein,increased high - density lipoprotein, and prolonged thrombin time （P 〈 0. 05 ）. Conclusion Tongx- inluo capsule significantly ameliorate symptoms of unstable angina peetoris, and improve the profile of lipid, coagulant function and ECG of myocardial ischemia.